Cyclosporine-A Nanotherapeutics Ameliorate Lupus Nephritis by Reprogramming the Gut-Microbial Metabolic Axis and Systemic Inflammation

Abstract

Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease fueled by abnormal immune responses and metabolic dysregulation, often leading to life-threatening lupus nephritis (LN). While Cyclosporine A (CsA) is a potent therapeutic agent, its clinical utility is severely constrained by systemic off-target toxicity and the necessity for frequent, high-dose administration. This study evaluates P2Ns-GA-CsA, a receptor-mediated, targeted nanoparticle formulation designed to modulate the core immune-metabolic axis in LN. Using an NZBWF1/J murine model, the administration of P2Ns-GA-CsA achieves enhanced renal protection compared to conventional oral CsA (Neoral), effectively suppressing serum creatinine, clusterin, and proinflammatory cytokines while preserving renal histoarchitecture. This therapeutic efficacy is realized with less than half the dosing frequency of the clinical standard, requiring 42 doses versus 98 doses over a 14 week period. Mechanistically, P2Ns-GA-CsA treatment is associated with the restoration of gut microbial homeostasis through the enrichment of protective taxa (Lactobacillus and Muribaculaceae), facilitating a metabolic shift. This modulation of the gut-microbial metabolic axis promotes the anti-inflammatory indole pathway while suppressing the pathogenic indoleamine 2,3-dioxygenase 1 (IDO1)-kynurenine pathway. These findings demonstrate that this targeted nanotherapeutic strategy decouples the immunosuppressive benefits of CsA from its systemic toxicity while restoring gut-renal integrity in autoimmune disorders.